Role of Antinuclear Antibodies in Primary Biliary Cholangitis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32701734.
- Also identified by DOI 10.14309/ajg.0000000000000765.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The identification of antinuclear antibodies specific for primary biliary cholangitis (PBC) has facilitated diagnosis in antimitochondrial antibody-negative individuals. Their presence may also have prognostic implication. In this edition of The American Journal of Gastroenterology, Reig et al. evaluate the frequency of PBC-specific antinuclear antibodies, their natural course and association with outcomes in 254 patients with PBC. Antibodies remained stable over time, and presence of antihexokinase1 and anti-sp100 was associated with shorter survival. Clinicians can request testing for PBC-specific antinuclear antibodies to minimize need for liver biopsy, but further research is needed to understand their role in disease prognostication.
Medical subject headings
- Leukocyte Disorders
- Liver Cirrhosis, Biliary